
Custom Differentiated iPSCs
At Greenstone Biosciences, we generate induced pluripotent stem cells (iPSCs) tailored to your research needs and differentiate them into specific human cell types, including cardiomyocytes, hepatocytes, and neurons. These physiologically relevant cells provide a direct window into human biology, enabling robust disease modeling, pathway analysis, and pharmacological testing.
Tailored to Your Research Goals
Every project is unique, and so are our iPSC differentiation strategies. We work closely with research teams to:
- Develop custom protocols that produce the exact cell type(s) required.
- Ensure consistency and scalability across batches for reproducible results.
- Provide isogenic and patient-specific cell lines for precision research.
Applications Across Discovery and Development
Custom differentiated iPSCs support a wide range of biomedical applications:
Disease Modeling
Study disease progression and cellular phenotypes in relevant human cell types.
Drug Discovery
Test compound efficacy and safety in cells that mimic patient biology.
Mechanistic Studies
Explore signaling pathways and gene function in specific cell types.
Regenerative Medicine Research
Generate clinically relevant cells for translational studies.

Consistency, Scalability, and Reproducibility
Our advanced differentiation protocols deliver cells that are highly reproducible and biologically robust, ensuring reliability across experiments. Whether your project requires small-scale exploratory work or large-scale screening, Greenstone’s platform provides a dependable supply of custom human cells.
Bridging the Gap Between Generic Models and Patient Biology
By delivering customized human iPSC-derived cells, Greenstone Biosciences bridges the gap between generic cell culture systems and disease- or patient-specific biology. This approach allows researchers to generate deeper insights, design better experiments, and accelerate the path to transformative therapies.
Build Patient-Relevant Cells
From cardiomyocytes to neurons, Greenstone delivers consistent, scalable, and patient-relevant iPSC-derived cells.